Iqos

From WikiMD's Medical Encyclopedia

Revision as of 23:22, 25 May 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

IQOS heated tobacco devices

Iqos (stylized as IQOS) is a line of heat-not-burn tobacco products manufactured by Philip Morris International. The device is an alternative to traditional cigarettes and is designed to heat specially designed tobacco units called HEETS or HeatSticks, rather than burning them. This process generates a nicotine-containing aerosol with fewer harmful chemicals than cigarette smoke.

History

Iqos was first introduced in Japan and Italy in 2014. Since then, it has been launched in numerous countries worldwide. The product was developed as part of Philip Morris International's efforts to create a smoke-free future by providing less harmful alternatives to smoking.

Technology

The Iqos device consists of three main components:

  • The Holder: This is the part of the device where the tobacco unit is inserted and heated.
  • The Charger: This is used to recharge the holder after each use.
  • The Tobacco Units: These are specially designed tobacco sticks that are heated by the holder.

The device heats the tobacco to a temperature of around 350°C, which is significantly lower than the 600°C to 900°C at which traditional cigarettes burn. This lower temperature reduces the levels of harmful chemicals produced.

Health Impact

While Iqos is marketed as a less harmful alternative to smoking, it is not without risks. The aerosol produced by Iqos contains nicotine, which is addictive, and other potentially harmful chemicals. However, studies have shown that the levels of harmful chemicals are significantly lower than those found in cigarette smoke.

Regulation

Iqos is subject to various regulations depending on the country. In some regions, it is classified similarly to traditional tobacco products, while in others, it is regulated as a separate category. In the United States, the Food and Drug Administration (FDA) authorized the marketing of Iqos as a modified risk tobacco product in 2020, recognizing that it could help reduce the risk of smoking-related diseases.

Market Presence

Iqos has gained significant market share in several countries, particularly in Japan, where it has become a popular alternative to traditional cigarettes. The product is also available in many European countries, as well as in Canada, Russia, and other markets.

Controversies

The introduction of Iqos has not been without controversy. Critics argue that the product may attract non-smokers, particularly young people, and could serve as a gateway to traditional smoking. There are also concerns about the long-term health effects of using heat-not-burn products, which are not yet fully understood.

See Also

References

External Links


   This article is a Tobacco-related stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes


Ad. Transform your life with W8MD's

GLP-1 weight loss injections special from $29.99 with insurance

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.